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was suggestive of superior reductions with degarelix. Sig-
nificantly more degarelix patients had improved quality of 
life (IPSS question) at week 12 (85 vs. 46%; p = 0.01). Mean 
prostate size reductions at week 12 were 42 versus 25% for 
patients receiving degarelix versus G+B, respectively (p = 
0.04; post hoc analysis). Most adverse events were mild/
moderate; more degarelix patients experienced injection 
site reactions whereas more G+B patients had urinary tract 
infections/cystitis. Conclusion: In 40 men with predomi-
nantly locally advanced PrCa and highly symptomatic LUTS, 
degarelix was at least non-inferior to G+B in reducing IPSS at 
week 12. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Lower urinary tract symptoms (LUTS) are common in 
elderly men with benign prostatic conditions or prostate 
cancer (PrCa) and frequently lead to them seeking medi-
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 Abstract 
 Introduction: No studies to date have assessed the efficacy/
tolerability of degarelix in the relief of lower urinary tract 
symptoms (LUTS) secondary to prostate cancer (PrCa). Meth-
ods: Patients were randomised to degarelix 240/80 mg or 
goserelin 3.6 mg + bicalutamide flare protection (G+B); both 
treatments were administered for 3 months. The primary 
endpoint was change in International Prostate Symptom 
Score (IPSS) at week 12 compared with baseline. Results: This 
study was stopped early due to recruitment difficulties. 40 
patients received treatment (degarelix n = 27; G+B n = 13); 
most had locally advanced disease and were highly symp-
tomatic. Degarelix was non-inferior to G+B in reducing IPSS 
at week 12 in the full analysis set (p = 0.20); the significantly 
larger IPSS reduction in the per-protocol analysis (p = 0.04) 
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cal care  [1] . For this reason, LUTS are often present at the 
time of diagnosis of PrCa. LUTS are commonly subdi-
vided into three categories: voiding or obstructive (hesi-
tancy, slow stream, intermittency, incomplete emptying); 
storage or irritative (frequency, urgency, nocturia, urgen-
cy urinary incontinence), and post-micturition (post-
void dribbling)  [2] . These symptoms can have a consider-
able impact on patients’ quality of life (QoL) and general 
well-being  [3] , especially when severe  [4] .
 Treatment of LUTS is related to the origin of the symp-
toms. In patients with PrCa, surgical intervention (radi-
cal surgery or transurethral resection) or radiation ther-
apy can have a positive impact. Radical prostatectomy 
removes the obstruction and may relieve voiding LUTS 
in men with localised PrCa  [5, 6] , while outcomes after 
transurethral prostatectomy in men with more extensive 
disease are less encouraging  [7] . Radiation therapy de-
creases gland size and may relieve symptoms but can al-
so exacerbate obstructive and irritative symptoms  [8, 9] . 
  -Blockers, 5  -reductase inhibitors and anticholinergics 
are used in the management of LUTS in patients with be-
nign prostatic conditions  [10] and also less commonly to 
alleviate symptoms in patients with PrCa undergoing ra-
diotherapy  [11] .
 Gonadotropin-releasing hormone (GnRH) agonists
or antagonists are commonly used to provide androgen 
deprivation in patients with PrCa  [12, 13] . However, the 
mechanism of action of GnRH agonists results in an ini-
tial surge in testosterone levels, which can stimulate tu-
mour growth and exacerbate clinical symptoms (‘clinical 
flare’)  [13] . GnRH agonists (+ antiandrogen flare protec-
tion) are also a standard treatment for patients with PrCa 
suffering LUTS. In contrast to GnRH agonists, GnRH 
blockers (antagonists) immediately block the GnRH re-
ceptor, resulting in a fast suppression of testosterone lev-
els, without a surge  [13] . A recent phase III trial (CS21) in 
patients with PrCa demonstrated that degarelix, a new 
GnRH blocker, was associated with significantly faster 
testosterone and prostate-specific antigen (PSA) suppres-
sion, and was at least as effective as the GnRH agonist 
leuprolide at suppressing testosterone to castrate levels 
over a 12-month study period  [14] . Furthermore, unlike 
leuprolide, degarelix was not associated with testosterone 
surge or microsurges, thus leading to more stable testos-
terone suppression as well as a longer time to biochemical 
progression  [15] .
 Here, we present results of the first study (CS28) to as-
sess the efficacy and tolerability of degarelix compared 
with a standard treatment (goserelin + antiandrogen 
flare protection) in the relief of LUTS secondary to PrCa.
 Patients and Methods 
 Study Design and Patients 
 CS28 was a multicentre, randomised, open-label, parallel-
group phase IIIb study that aimed to demonstrate that LUTS relief 
with degarelix was non-inferior to goserelin + antiandrogen (bi-
calutamide) flare protection based on the reduction in Interna-
tional Prostate Symptom Score (IPSS) at week 12 versus baseline. 
Patients were randomised 3: 1 to either a degarelix starting dose 
of 240 mg for 1 month followed by monthly maintenance doses
of degarelix 80 mg, or to goserelin 3.6 mg/month + bicalutamide 
50 mg/day (G+B). Bicalutamide was initiated 3 days before the 
first goserelin injection and continued for 14 days afterwards (to-
tal treatment duration 17 days). Patients were treated for a total of 
3 months. Degarelix was reconstituted in water and the starting 
dose administered as two 3-ml deep subcutaneous injections into 
the abdominal region; maintenance doses were administered as 
single 4-ml subcutaneous injections. Goserelin implants were in-
serted subcutaneously into the abdominal wall. Bicalutamide was 
administered once daily orally.
 Initially, adult patients with histologically confirmed treat-
ment-naïve PrCa (Gleason graded, T3/4) and LUTS, for whom 
endocrine therapy was indicated, were to be included. However, 
as the recruitment rate was low, inclusion criteria were widened 
to include patients with any stage PrCa and those who had re-
ceived prior treatment with a 5  -reductase inhibitor or an   -ad-
renoceptor antagonist. However, therapy must have ceased for 
 6 6 months for patients treated with a 5  -reductase inhibitor and 
for  6 8 weeks for   -adrenoceptor antagonist treatment, prior to 
study entry. Prior transurethral resection of the prostate was not 
permitted. Patients were also required to have a serum PSA level 
 1 10 ng/ml, an IPSS  6 12, peak urinary flow (Q max )  ̂  12 ml/s 
(voided volume  6 150 ml), a prostate size  1 30 ml (measured by 
transrectal ultrasound), and an Eastern Cooperative Oncology 
Group (ECOG) performance status  ̂  2.
 Independent ethics committees reviewed the study protocol, 
any amendments, and also advertisements used for recruitment. 
They also reviewed the patient information sheet and the informed 
consent form, their updates (if any), and any written materials giv-
en to the patients. The trial was performed in accordance with the 
Declaration of Helsinki, in compliance with the approved protocol 
and amendments, the International Conference on Harmonisa-
tion Guidelines for Good Clinical Practice, the European Union 
Clinical Trials Directive and with local regulatory requirements. 
Written informed consent was obtained from each patient before 
any study-related procedure was performed.
 Endpoints 
 Change in IPSS at week 12 compared with baseline was the 
primary endpoint in this study. Secondary efficacy endpoints al-
so compared data at certain study time points with those at base-
line, including: IPSS at weeks 4 and 8; Q max at weeks 4, 8 and 12; 
prostate size (measured by transrectal ultrasound) at week 12; 
changes in serum testosterone concentration and PSA levels at 
weeks 4, 8 and 12. QoL (in relation to urinary symptoms) at week 
12 was also compared with the baseline assessment and was eval-
uated by an additional question on the IPSS questionnaire. The 
response to this question was analysed separately and was not in-
cluded in the total IPSS score. The question was, ‘If you were to 
spend the rest of your life with your urinary condition the way it 
 Degarelix versus Goserelin in the Relief 
of Lower Urinary Tract Symptoms 
 Urol Int 2013;90:321–328 
DOI: 10.1159/000345423
323
is now, how would you feel about that?’ The possible answers 
ranged from ‘delighted’ (a score of ‘0’) to ‘terrible’ (a score of ‘6’). 
The frequency and severity of adverse events (AEs) occurring 
during this study were also recorded.
 Statistical Methods 
 All analyses were performed, and summary statistics calcu-
lated, using SAS  version 9.2. Using a non-inferiority margin of
3 points for the true difference in mean change from baseline
in total IPSS score between degarelix and G+B, the sample t test 
(  = 0.05, two-sided), and assuming a standard deviation of the 
change from baseline in total IPSS score of 6.5 points at week 12, 
201 degarelix patients and 67 G+B patients were required to dem-
onstrate non-inferiority with 90% probability under the hypoth-
esis of truly equal treatment effects. Since non-inferiority was also 
planned to be demonstrated in the per-protocol (PP) population, 
an additional 5% was added to cover for any anticipated protocol 
violators, to arrive at a planned total population of 280 patients 
(210 on degarelix; 70 on G+B). The primary analysis was an anal-
ysis of covariance (ANCOVA) of the change from baseline in total 
IPSS score at week 12, using the last observation carried forward 
(LOCF) approach, with baseline total IPSS and age as covariates, 
and country/region and treatment as factors in both the full and 
PP analysis populations. The trial was considered positive if the 
treatment difference for degarelix versus G+B in the adjusted 
mean change from baseline in total IPSS was statistically signifi-
cantly smaller (two-sided at   = 0.05 level) than   = 3 points in 
both the full and PP analysis sets.
 The full analysis set was defined as all patients who received 
at least one dose of study drug and had at least one post-dose ef-
ficacy assessment. The PP analysis set was defined as patients who 
were included in the full analysis set who had no major protocol 
deviations. Observed cases sensitivity analyses (i.e. completer 




 The trial was stopped early due to the low recruitment 
rate and this led to a reduced sample size. In total, 42 pa-
tients were randomised; 40 patients received at least one 
dose of study treatment and had at least one post-dose ef-
ficacy assessment and so were included in the full analy-
sis set. Baseline characteristics were generally well bal-
anced between groups ( table  1 ); most had locally ad-
vanced or metastatic PrCa, high PSA levels and were 
highly symptomatic.




Goserelin 3.6 mg +
bicalutamide 
(n = 13)
Age, years, median (range) 68 (53–87) 72 (57–85)
Testosterone level, ng/ml, median (range) 4.2 (1.1–6.7) 3.9 (2.7–7.4)
PSA level, ng/ml, median (range) 54.5 (8–1,914) 41.1 (14.6–348)
T staging, n (%)
T1/2 5 (19) 2 (15)
T3/4 21 (78) 11 (85)
TXa 1 (4) 0 (0)
M staging, n (%)
M0 4 (15) 2 (15)
M1 10 (37) 4 (31)
MXb 9 (33) 7 (54)
Gleason score, n (%)
5–6 2 (7) 0 (0)
7–10 25 (93) 13 (100)
ECOG performance status, n (%)
0: fully active 22 (81) 11 (85)
1: restricted, but ambulatory 4 (15) 1 (8)
2: ambulatory, unable to carry out work 1 (4) 1 (8)
IPSS total score, mean (SE) 20.1 (1.1) 21.1 (1.6)
IPSS quality of life score, mean (SE) 3.6 (0.3) 3.2 (0.5)
Qmax, ml/s, mean (SE) 9.3 (0.8) 8.3 (0.8)
Prostate volume, ml, mean (SE) 53.5 (5.5) 50.3 (4.5)
  a Primary tumour unassessable. bDistant disease unassessable.
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 International Prostate Symptom Score 
 Total Score.  Degarelix was non-inferior to G+B in re-
ducing IPSS at week 12 ( fig. 1 ;  table 2 ); mean total IPSS 
showed clinically significant ( 1 3 points)  [16] decreases 
from baseline in both groups. The upper limit of the two-
sided 95% confidence interval (CI) for the adjusted mean 
difference between the two treatment groups for total 
IPSS at week 12 was 1.6 and –0.3, for the full and PP anal-
ysis sets, respectively. These were below the non-inferior-
ity margin of 3, and so non-inferiority could still be con-
cluded despite the small number of patients in each group. 
Moreover, for the PP analysis set, the upper limit of the 
two-sided 95% CI for the difference between the two treat-
ment groups for total IPSS at week 12 (–0.3) was below 
zero, suggesting statistical superiority of degarelix over 
G+B (p = 0.04) in IPSS reduction ( fig. 1 ;  table 2 ). Overall, 
numerically greater reductions in mean total IPSS score 
were observed at weeks 4, 8 and 12 with degarelix com-
pared with G+B.
 Individual Items.  Compared with those receiving 
G+B, numerically greater proportions of degarelix-treat-
ed patients experienced improvements in the following 
individual items on the IPSS questionnaire at week 12: 
incomplete emptying, frequency, intermittency, and noc-
turia ( fig. 2 ). Numerically greater improvements in weak 
stream and straining symptoms were seen in the G+B 
group.  Mean QoL scores showed a decrease (i.e. QoL im-
proved) from baseline at each visit in both treatment 
groups but significantly more degarelix patients had im-
proved QoL at week 12 compared with those receiving 
G+B (85% (23/27) versus 46% (6/13); p = 0.01) ( fig. 2 ). The 
mean (standard error (SE)) decrease from baseline in 
scores at weeks 4, 8 and 12 was also numerically higher 
in the degarelix group (–1.0 (0.2), –1.5 (0.3) and –1.8 (0.3), 
respectively) than in the G+B group (–0.5 (0.4), –0.7 (0.7) 
and –0.6 (0.5), respectively).  At week 12, numerically 
more patients in the G+B group experienced worsening 
of emptying, intermittency, urgency, weak stream and 
27 2726 26 26D
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Degarelix (D) Goserelin + bicalutamide (G+B)
12 LOCF
Difference at week 12 (primary endpoint): estimate (95% CI) from ANCOVA with treatment and
country as factors and age and baseline total IPSS score as covariate
Non-inferiority margin = 3
 Fig. 1. Mean (95% CI) change from base-
line in total IPSS over time: full analysis set 
(LOCF analysis) (a) and PP analysis set 
(LOCF analysis) (b). 
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straining symptoms, and QoL ( fig.  2 ). In contrast, nu-
merically more degarelix patients had worsened noctu-
ria.
 Prostate Size and Q max 
 Decreases in prostate size were observed in both 
groups at week 12, but the magnitude of decrease was nu-
merically greater with degarelix than with G+B. In the 
full analysis set, adjusted mean (SE) change from baseline 
was –21.8 (2.7) versus –14.0 (3.9) ml in the two groups, 
respectively; treatment difference (in favour of degarelix): 
–7.8; 95% CI –17.3, 1.6; p = 0.10. This equates to 42% (4.5) 
versus 25% (6.5) mean (SE) percentage reductions in 
prostate volume at week 12 versus baseline for patients 
receiving degarelix versus G+B, respectively; treatment 
difference (in favour of degarelix): –17%; 95% CI –33.0, 
–1.3; p = 0.04 (post hoc analysis). In the PP analysis, mean 
(SE) percentage reductions in prostate size at week 12 
were –42% (4.7) versus –29% (8.0); p = 0.16, in the degare-
lix and G+B groups, respectively.
 Increases in Q max were observed in both groups at 
weeks 4, 8 and 12. In the full analysis set at week 12, the 
mean (SE) change from baseline was 3.3 (1.2) versus 1.3 
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 Fig. 2. Change from baseline (improved/unchanged/worse) in individual IPSS items at week 12 (full analysis set; LOCF analysis). 

















Mean (SE) –11.6 (1.3) –8.6 (1.9) –3.0 (–7.5, 1.6) 0.20
PP analysis set
Number 26 11




Mean (SE) –11.6 (1.3) –7.4 (1.8) –4.2 (–8.7, 0.3) 0.06
PP analysis set
Number 25 8
Mean (SE) –11.7 (1.3) –6.0 (2.2) –5.7 (–11.0, –0.4) 0.04
a Estimates from an ANCOVA with treatment and country as 
factors and age and baseline IPSS value as covariates. b p value for 
testing superiority.
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tively; treatment difference (in favour of degarelix) was 
2.0 ml/s (95% CI –2.0, 6.1; p = 0.32). Similar changes in 
Q max were observed in the PP analyses.
 Testosterone and PSA Control 
 All patients in the degarelix group maintained serum 
testosterone at or below castrate levels (0.5 ng/ml) at 
weeks 4, 8 and 12. Results were similar in the G+B group, 
although 1/13 patients (8%) had testosterone  1 0.5 ng/ml 
at week 4. Mean testosterone levels were reduced by  1 97% 
in the degarelix treatment group at these time points; 
mean testosterone levels were reduced by 84% at week 4 
in the G+B group and by  1 97% at weeks 8 and 12.
 PSA levels were reduced by  1 90% at week 12 in both 
the degarelix and G+B groups (mean reduction 92 versus 
97%, respectively). Median PSA levels at this time point 
were  ! 2 ng/ml in both groups.
 Tolerability 
 Overall, 52% (14/27) versus 54% (7/13) of patients in 
the degarelix versus G+B groups experienced an AE dur-
ing the study, most of which were mild (common toxicity 
criteria (CTC) grade 1) or moderate (CTC grade 2) in in-
tensity. Injection site events (33% (9/27 patients)) and hot 
flushes (19% (5/27 patients)) were the most common AEs 
in the degarelix group; hot flushes, cystitis, urinary tract 
infections (UTI) and metastases to bone (15% each (2/13 
patients)) were most common in the G+B group.
 There were no deaths, discontinuations due to AEs, 
serious AEs or severe (CTC grade 3–5) AEs in the degare-
lix group. In those receiving G+B, 1/13 patients (8%) died 
from renal failure and also had several other serious AEs 
(hepatic failure, PrCa progression and lower urinary 
tract obstruction). Severe urinary retention occurred in 
another patient receiving G+B. 
 Discussion 
 The efficacy and safety of degarelix as a PrCa treat-
ment has been well established in an extensive clinical tri-
al programme  [14, 17, 18] , but its effect on LUTS has not 
been studied previously. The current study, therefore, 
aimed to determine the efficacy and safety of degarelix 
versus G+B in men with LUTS secondary to PrCa. The 
target patient population was difficult to recruit fully at 
the participating sites. Unfortunately, despite several ini-
tiatives to improve recruitment (e.g. protocol amend-
ments to broaden the inclusion criteria), this trial was 
stopped early with 42 patients randomised. Most of these 
patients had highly symptomatic disease, which reflects 
the original stringent recruitment criteria. However, be-
cause the effect of degarelix on IPSS reduction was great-
er than expected, it was still possible to show that this 
agent was non-inferior to G+B at reducing IPSS at week 12 
in the full analysis set, despite the reduced sample size. 
The fact that the observed SD (6.7) was very close to the 
SD assumed in the original power calculation (6.5), also 
provides reassurance that the original power calculations 
were appropriate. Furthermore, sensitivity analyses in the 
PP population suggested that these results were robust 
and the significantly larger reductions in IPSS in these 
analyses are suggestive of degarelix being superior to G+B 
for this endpoint. This result is consistent with the statis-
tically significant benefits observed for degarelix in per-
centage change in prostate size and QoL (IPSS question). 
There were also numeric improvements seen in both se-
lected voiding (incomplete emptying and intermittency) 
and storage (frequency and nocturia) symptoms, as well 
as Q max, although these did not reach statistical signifi-
cance. Due to the low number of patients included, any 
imbalances between groups could have biased the results. 
However, it is important to note that these data were cor-
rected via ANCOVA for various baseline factors (country, 
age and baseline value). Nonetheless, it must be acknowl-
edged that the smaller the sample size, the greater the like-
lihood that any observed differences between treatments 
could be due to chance, and so these results should be in-
terpreted within the context of the size of the study.
 The numerically higher frequency of cystitis/UTI in 
patients receiving G+B seems to be in agreement with the 
less pronounced effect on prostate size and lower urinary 
tract obstruction. The mean percentage reduction in 
prostate volume observed for G+B at week 12 in the pres-
ent study (25%) is similar to the mean 3-month reduction 
of 31% seen in patients receiving buserelin + nilutamide 
in a recent neoadjuvant study  [19] . Other combination 
neoadjuvant treatments such as bicalutamide + dutaste-
ride have produced similar prostate size reductions to the 
GnRH agonists (34% reduction after 3 months)  [20] . In 
the present study, degarelix achieved a mean reduction of 
42% at week 12; a similar reduction was only seen after
6 months’ buserelin + nilutamide treatment. Interesting-
ly, benefits in prostate size reduction have also been noted 
for degarelix versus GnRH agonists in animal models of 
PrCa  [21] .
 Testosterone control appeared to be similar between 
groups in this study; however, as the first post-baseline 
measurement was at week 4, early differences would have 
been missed. Any initial testosterone flare produced by 
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GnRH agonists may translate into a delay in the onset of 
tumour inhibition (and, therefore, potentially a delay in 
symptom control) compared with degarelix, which offers 
immediate testosterone suppression. The apparent effica-
cy benefits of degarelix may relate to the differences in 
mode of action between these two agents; however, the 
differences in prostate size and Q max may not be solely at-
tributable to differences in the onset of testosterone sup-
pression. This raises the possibility of other driving mech-
anisms that were not directly addressed by the present 
study. For example, experimental observations suggest 
that GnRH antagonists may have direct effects on prostate 
cells including pro-apoptotic  [22] and antiproliferative ef-
fects  [23] , regulation of growth hormones  [24] , and even 
anti-inflammatory effects  [25] . However, such preclinical 
observations are yet to be verified in patients with PrCa. 
GnRH antagonists are also associated with a more pro-
found and sustained suppression of follicle-stimulating 
hormone levels compared with GnRH agonists  [14] . This 
observation is of interest as evidence is accumulating that 
follicle-stimulating hormone may have a direct role in the 
pathogenesis and progression of PrCa  [26–30] . Together, 
such effects could in theory contribute to a more rapid 
and/or more pronounced shrinkage of prostate tumours 
during treatment with degarelix as compared with G+B.
 Overall, the tolerability profiles of these treatments 
were as expected for a population of men with LUTS sec-
ondary to PrCa. These data were also in line with previ-
ous findings for degarelix versus a GnRH agonist  [14] ; 
injection site events were more common with degarelix 
and UTIs/cystitis/obstruction were more common with 
G+B. Both treatments were generally well tolerated, with 
most AEs being mild or moderate in intensity. However, 
1 patient experienced serious AEs (one of which was fatal) 
and another had a severe AE related to urinary retention 
(both patients received G+B). These AEs are in line with 
the less pronounced prostate shrinkage and Q max im-
provements seen in this group, which in turn may be a 
consequence of its different mode of action. Ultimately, 
the overall efficacy and tolerability findings translated 
into improved QoL, irrespective of treatment received. 
However, significantly more degarelix patients experi-
enced a QoL improvement at week 12 compared with 
those receiving G+B.
 Conclusions 
 Degarelix was non-inferior to G+B at reducing LUTS 
at week 12 in these 40 patients with mostly highly symp-
tomatic, advanced disease; the PP analyses were sugges-
tive of degarelix being superior to G+B for this endpoint. 
Significantly greater improvements in percentage change 
in prostate size from baseline and QoL were also seen in 
the degarelix group. These results are supported by a larg-
er numeric improvement in Q max and a lower incidence 
of urinary AEs during degarelix treatment. Collectively, 
these observations suggest that the greater LUTS im-
provement could be attributed to a more pronounced 
shrinkage of the prostate and consequently improved uri-
nary flow and bladder emptying in the patients treated 
with degarelix. Nonetheless, these results should be inter-
preted within the context of the size of the study.
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